Radio and PodcastRadio and PodcastLive Radio & Podcasts
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib artwork
Science & Medicine

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer by American Medical Association

Nov 21, 202418:46Science & Medicine

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Cont...

About This Episode

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib is an episode from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients...

Podcast

This episode belongs to JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Nov 21, 2024, 18:46 long, audio available.

Related Episodes

Continue listening to more episodes from JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patients with cancer.